Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TCR2 Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is \> 18 years of age at the time the Informed Consent is signed.
Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer
Patient's tumor has been reviewed with confirmed positive MSLN expression on \>/= 50% of tumor cells that are 1+, 2+ and/or 3+ by immunohistochemistry. Patients with epithelioid MPM, confirmation of MSLN expression is not required prior to enrollment.
Prior to TC-510 infusion, patients must have received at least 1 but no more than 5 systemic therapies for metastatic or unresectable disease with more details provided in the protocol
Patients has an ECOG performance status 0 or 1
Patient is fit for leukapheresis and has adequate venous access for the cell collection.
Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol
You may not be if
Inability to follow the procedures of the study
Known or suspected non-compliance, drug, or alcohol use
Clareo Health | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
